Bringing the fundamentals into focus…
Back to Eton Pharmaceuticals, Inc.
How Eton Pharmaceuticals, Inc. stacks up
ETON · against 456 other Healthcare companies of similar size
Valuation
39/ 100
Below the middle of the pack.
Ranked #288 of 457 · scores higher than 36% of peers
Bars: peers in each 10-point band of the valuation score36 peers with a valuation score of 30–39, including ETON · Click a bar to see the companies
Why valuation scores 39?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield, which is weaker than most Healthcare peers.
- less operating profit (EBITDA) for the company's total value: weaker than 62% of peers. EBITDA yield: 1.4% vs peer median 4.0%
- Earnings yield is close to the peer norm. Earnings yield: 0.9% vs peer median 1.5%
- Free cash flow yield is close to the peer norm. Free cash flow yield: 1.0% vs peer median 0.0%
Metric by metric
Position: dot = ETON, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | ETON | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 445 reported | 0.8% | 1.5% | 43% | 30% | |
| EBITDA yieldHigher is better · 460 reported | 1.7% | 4.5% | 36% | 50% | |
| Free cash flow yieldHigher is better · 210 reported | -0.0% | -0.5% | 54% | 20% | |
| Book yieldHigher is better · 449 reported | 3.2% | 39.2% | 6% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around ETONScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score